Trial Profile
A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients Who Have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-698/ECHO-303
- Sponsors Incyte Corporation
- 16 Dec 2020 This trial has been Discontinued in Germany, according to European Clinical Trials Database record.
- 27 Aug 2020 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 26 Aug 2020 Status changed from active, no longer recruiting to completed.